Thermo Fisher Scientific’s PPD clinical research business has launched the PPD DCT Network to back international investigators and research sites that take part in decentralised clinical trials (DCTs) for pharmaceutical and biotech customers.
The network’s foundation will be a new DCT eLearning certification programme created in partnership with the Site Advocacy Group process of the Society for Clinical Research Sites (SCRS).
An international organisation, SCRS supports over 9,500 sites in 47 countries.
Sites and investigators will leverage the DCT network to obtain practical training that leads to membership in the network.
A devoted DCT network manager will work with investigators and sites to manage information sharing, best practices, and guidance among the members of the network as the DCT landscape evolves.
The network will be accessible to the complete range of sites that PPD presently collaborates with to offer DCT studies for customers.
The network will also back sites with the evolution of DCTs and as clinical researchers seek to enhance the patient experience in trials by providing options such as home health care, telemedicine, and mobile sites that permit more individuals to take part.
The DCT certification programme has two levels. The first tier will offer a foundational introduction to DCTs while the second tier will expand on the first level by delivering in-depth expertise for application.
Thermo Fisher Scientific clinical research digital and decentralised solutions vice-president Tim Rich said: “As a global leader in the design, strategy, and delivery of DCTs, we are pleased to establish this global network to offer our customers trained investigators and sites focused on supporting the ongoing development and deployment of DCTs.
“Through the Site Advocacy Group process, as well as our collaboration with investigators and sites experienced in delivering DCTs, we are combining efforts to enhance consistency and quality of delivery to be our customers’ DCT partner of choice.
“In the end, our goal is to enable more patients, including those from diverse, traditionally underrepresented populations, to participate in clinical research.”